trial

Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia

NCTId NCT05368558
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 34 (actual)
Sponsored by AbbVie
Primary completion 2024-09-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
34 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-08-18
Primary completion
2024-09-20
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cariprazine (Vraylar)

Sponsors

AbbVieLead Sponsor

Sites

52 total
Akita, JapanNarita-shi, JapanFukuoka, JapanFukuoka, JapanOmuta-shi, JapanGifu, JapanToki-shi, JapanKure, JapanKure-shi, JapanSapporo, JapanSapporo, JapanSapporo, Japan

Linked catalysts

1
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazin — primary completion2024-09-20

Facts & assertions

4 sourced
Enrollment
34
Phase
PHASE3
Primary Completion Date
2024-09-20
Status
TERMINATED
relationships
The graph out of here
drug
Cariprazine (Vraylar)
drug
lead_sponsor
AbbVie
company
indication
Schizophrenia
indication
Schizophrenia
indication